# Study of GDX012 in Patients With MRD Positive AML

> **NCT05001451** · PHASE1 · TERMINATED · sponsor: **GammaDelta Therapeutics Limited** · enrollment: 3 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** GDX012 Suspension for IV Infusion

## Key facts

- **NCT ID:** NCT05001451
- **Lead sponsor:** GammaDelta Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-13
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-06-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** This was a business decision to discontinue this clinical trial. The decision is not related to the safety of the investigational product, GDX012.
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001451, "Study of GDX012 in Patients With MRD Positive AML". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05001451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*